Stress management

Suggested

2 studies · 1 recommendation

Last updated: February 23, 2026

Suggested2 studies

Stress management supports immune function and symptom control in cancer patients

A prospective cohort study of 99 advanced cancer patients found that higher perceived stress, measured via the Perceived Stress Scale, predicted subsequent dysregulation of CD16+ and CD56+ natural killer cell subsets — immune components critical for identifying and destroying tumor cells. Cross-lagged panel analyses confirmed a temporal relationship where stress precedes immune decline, potentially facilitating tumor growth or metastatic spread. A systematic review of 15 studies further identified relaxation techniques as effective non-pharmacological interventions for managing cancer-related pain and dyspnea, with multimodal approaches integrating stress reduction yielding the strongest symptom control. Across these 2 studies, stress management emerges as a practical adjunct to standard cancer care, supporting both immune resilience and quality of life.

Evidence

Control of Pain and Dyspnea in Patients with Oncologic Disease in Acute Care: Non-Pharmacological Intervention

Authors: Fonseca, C, Lopes, M. J., Mendes, F, Parreira, P., Ramos, A., Tavares, AP

Published: January 1, 2017

A systematic review of 15 articles from EBSCO databases including MEDLINE with Full Text, CINAHL Plus with Full Text, and British Nursing Index (2009–2015), combined with guidelines from the Oncology Nursing Society (2011), National Comprehensive Cancer Network, and Cancer Care Ontario, identified relaxation techniques among non-pharmacological measures that increase health gains for oncologic symptom control. The review concluded that comprehensive and multimodal approaches integrating relaxation alongside other interventions provide adequate pain and dyspnea management.

View Source →

Prospective Analysis of Stress and Immunity in Advanced Cancer

Authors: Ikpeama, Uzoh Erick

Published: May 9, 2011

In this prospective cohort study of 99 patients with biopsy, radiological, or biological evidence of advanced cancer, stress was measured using the Perceived Stress Scale and immune function assessed via CD16+ and CD56+ lymphocyte subsets. Mann-Whitney U tests revealed significant differences in CD16 and CD56 levels between high-stress and low-stress groups at multiple time points. Cross-lagged panel analyses demonstrated that higher perceived stress predicted abnormal levels of both CD16+ and CD56+ at subsequent time points, indicating a temporal relationship where stress precedes immune dysregulation. The authors conclude this dysregulation could decrease the body's ability to identify and destroy new tumor cells, potentially contributing to primary tumor growth or metastatic spread.

View Source →